brexucabtagene autoleucel
gilead
['mantle,(-dismantle)', 'lymphoma', 'zuma-2']
three-year follow-up of kte-x19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the zuma-2 study 
Chief, Stem Cell Transplantation and Cellular Therapy. John Theurer Cancer Center, NJ. Opinions are my own